林成俊醫師

林口長庚醫院 胃腸肝膽科
台灣肝癌醫學會

From Mechanism to Clinical Effects -
The similarities and differences between TKIs and anti-VEGF antibody

Summary
1. Anti-angiogenic drugs have different safety and efficacy profiles according to their pharmacologic effects
2. Hypertension, proteinuria, and bleeding risk may be the class effect of VEGFR inhibition
3. Off-target effects of TKIs may be associated with more GI or skin-related AEs
4. Adding bevacizumab to atezolizumab is proved to enhance the antitumor effects of immunotherapy
5. Whether other combinational therapy may yield similar efficacy require more studies

相關資訊

提升醫療品質

Promoted to the medical quality

台灣肝癌醫學會 (TLCA)
Leave a comment

各位會員您好,如果您針對活動內容有任何想法,歡迎留下您的回饋與建議,我們將依據您們的回饋來調整接下來幾集的影片內容,謝謝您對學會的支持與指教。

留言功能僅在新影片上傳後三天內開啟。

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.